Home › Peanut Hypersensitivity › Michigan › Ann Arbor
Peanut Hypersensitivity clinical trials in Ann Arbor, MI
6 studies for Peanut Hypersensitivity are looking for participants at sites in and around Ann Arbor (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A 52-week Study of Remibrutinib in IgE-mediated Food Allergy
RecruitingPhase 3
- Respiratory Medicine Research Institute of Michigan, Ypsilanti · 7 mi away
Efficacy of Tezepelumab in Peanut Oral Immunotherapy
RecruitingPhase 2
- The University of Michigan: Division of Allergy and Clinical Immunology, Ann Arbor
Study of Oral Food Challenge Biomarkers (SAFER)
RecruitingObservational study
- The University of Michigan: Division of Allergy and Clinical Immunology, Ann Arbor
Study to Evaluate the Safety, Pharmacokinetic, and Pharmacodynamic Effects of MY006 in Healthy Volunteers and Patients With Peanut Allergy
RecruitingPhase 1Healthy volunteers welcome
- Mary H. Weiser Food Allergy Center (MHWFAC) University of Michigan - Michigan Medicine, Ann Arbor
Phase 2b Study of RPT904 as Monotherapy in Participants With IgE-Mediated Food Allergy
RecruitingPhase 2
- University of Michigan, Ann Arbor
Safety of MOON101 for the Treatment of Peanut Allergy
RecruitingPhase 1
- University of Michigan, Ann Arbor
Peanut Hypersensitivity trials in other cities
- Boston, MA6 studies
- Little Rock, AR6 studies
- Durham, NC4 studies
- New York City, NY4 studies
- Cincinnati, OH3 studies
- Aurora, CO3 studies
- Atlanta, GA3 studies
Other studies in Ann Arbor
- Prostate Cancer27 studies
- Breast Cancer26 studies
- Non-Small Cell Lung Cancer26 studies
- Cancer (all types)25 studies
- Colorectal Cancer23 studies
- Lung Cancer23 studies
- Heart Failure22 studies
- Acute Myeloid Leukemia17 studies
- Cardiovascular Disease16 studies
- Pancreatic Cancer14 studies
- Melanoma12 studies
- Kidney Cancer (Renal Cell Carcinoma)12 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.